Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies
June 29 2023 - 5:09PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
Stratys™ system for high throughput optical genome mapping (OGM)
and VIA™ software for visualization, interpretation and reporting
of genome analysis for OGM, microarrays and next-generation
sequencing (NGS) data in one integrated software platform. VIA
further incorporates these data into an intuitive and powerful
workflow for hematologic malignancies.
Bionano’s Stratys system for OGM offers increased
throughput capabilities to address the needs of mid and high-volume
users. The throughput of the Stratys instrument is up to
four times greater than that of Bionano’s Saphyr instrument, it is
compatible with the latest G2 chemistry and has a potential
sample-to-answer time of 3 days for hematological samples
interrogated across the whole genome at high sensitivity to rare
variants. The system is designed for maximum lab flexibility by
enabling up to 12 single access chips, accessible as they complete
runs, without the need to batch multiple samples on a consumable.
Commercial rollout of the system will initially include 10 early
access sites who will be given the opportunity to adopt it as
manufacturing capacity is being expanded, with full capacity
expected by early 2024.
VIA software replaces
NxClinical software with a simple
and integrated workflow for visualization, interpretation and
reporting for data types that are standard across molecular
pathology and cytogenomics: OGM, NGS and microarrays. The
VIA software is designed to automate variant calling, annotation
and interpretation, for enhanced contextualization across multiple
variant types and accelerated time to results at a reduced cost.
This release also offers a new hematologic malignancy workflow,
including curated resources that represent guideline-based targets
applicable to hematological disease. A workflow focused on genetic
disease is expected later in 2023. VIA installations will begin at
the end of July 2023.
“We are pleased to announce two exciting new products that we
believe will accelerate adoption of OGM by higher volume users and
expand utilization: the Stratys system for OGM and our VIA software
with a workflow for hematologic malignancies. Stratys is the next
evolution in the OGM workflow and offers labs with high sample
volumes greater sample flexibility across a variety of research
applications, with enhanced throughput and reduced sample-to-answer
time. VIA replaces NxClinical with a platform that analyzes OGM
data alongside other data types and creates a powerful and
efficient workflow for data from OGM, NGS and microarrays to be
reported separately or integrated into a single report to
contextualize all classes of genomic variation and drive meaningful
insights,” stated Mark Oldakowski, chief operating officer of
Bionano.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, commented, “These are the product launches we believe will
overcome barriers faced by high-volume users seeking to run OGM on
a routine basis in clinical research – faster data generation and
streamlined analysis and reporting. The prowess of Stratys for OGM
is incredible and the utility of VIA as the platform for
visualization, interpretation and reporting of cytogenomic data
goes well beyond just OGM users as it touches the NGS communities
in cancer and genetic diseases.”
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “plan,” “potential,” “will” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the potential of the Stratys system to increase
sample throughput compared to the Saphyr system; the ability of the
Stratys system workflow to provide a sample to answer time of 3
days for hematological samples; ; the ability of the Stratys system
to maximize lab flexibility; the ability the VIA software to
automate variant calling, interpretation and annotation, for
enhanced contextualization across multiple variant types and
accelerated time to results at a reduced cost; the potential of the
Stratys system and the VIA software to accelerate the adoption of
OGM and overcome barriers to adoption of OGM by high-volume users;
our ability to drive adoption of the Stratys system and the VIA
software; and execution of our stated strategies and plans. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of geopolitical and
macroeconomic developments, such as recent and potential future
bank failures, the ongoing Ukraine-Russian conflict, and related
sanctions, and the COVID-19 pandemic, on our business and the
global economy; the failure of the Stratys system to increase
sample throughput; the failure of the Stratys system to increase
sample throughput compared to the Saphyr system; the failure of the
Stratys system to provide a sample to answer time of 3 days for
hematological samples; the failure of the VIA software to automate
variant calling, interpretation and annotation, for enhanced
contextualization across multiple variant types and accelerated
time to results at a reduced cost; the failure of the Stratys
system and the VIA software to accelerate the adoption of OGM and
overcome barriers to adoption of OGM by high-volume users; the
failure of our ability to drive adoption of the Stratys system and
the VIA software; execution of our stated strategies and plans ;
general market conditions; changes in the competitive landscape and
the introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts and our ability to
continue as a “going concern”; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2022
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024